Table 2 Effect of PCC0208027 on NSCLC cell viability.

From: PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

Cell lines

Characterization

IC50 (nM)

PCC0208027

Erlotinib

Osimertinib

Poziotinib

HCC827

EGFR (Del E746_A750))

4.22 ± 0.51

3.71 ± 1.89

1.09 ± 0.22

1.72 ± 0.32

NCI-H1975

EGFR (L858R/T790M)

11.11 ± 4.39

>1,000

7.25 ± 2.30

8.78 ± 3.03

Calu-3

HER-2 (WT, amplified)

6.07 ± 0.29

>1,000

469.96 ± 7.30

2.47 ± 0.52

NCI-H1781

HER-2 (G776V, Cins)

5.97 ± 1.37

>1,000

842.3 ± 33.95

6.17 ± 0.42

A549

K-ras mutation (G12S)

>1,000

>1,000

>1,000

>1,000

  1. Values are presented as mean ± s.d. (n = 3).
Back to article page